EFFECTS OF HTD1801 (BERBERINE URSODEOXYCHOLATE) IN SUBJECTS WITH PRIMARY SCLEROSING CHOLANGITIS PREVIOUSLY EXPOSED TO UDCA

被引：0
|
作者：
Kowdley, Kris V. [1 ,2 ]
Forman, Lisa [3 ]
MacConell, Leigh [4 ]
Hirschfield, Gideon [5 ]
机构：
[1] Liver Inst Northwest, Seattle, WA USA
[2] Washington State Univ, Elson S Floyd Coll Med, Pullman, WA 99164 USA
[3] Univ Colorado, Boulder, CO 80309 USA
[4] Hightide Therapeut, Shenzhen, Peoples R China
[5] Univ Toronto, Toronto Ctr Liver Dis, Toronto, ON, Canada
来源：
HEPATOLOGY | 2021年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1267
引用
收藏
页码：760A / 761A
页数：2
相关论文
共 24 条
  • [1] PROOF OF CONCEPT STUDY OF HTD1801 (BERBERINE URSODEOXYCHOLATE) IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS NOT PREVIOUSLY EXPOSED TO UDCA
    Hirschfield, Gideon
    Forman, Lisa
    Eksteen, Bertus
    Gunn, Nadege T.
    Sundaram, Vinay
    Landis, Charles
    Harrison, Stephen A.
    Kohli, Anita
    Levy, Cynthia
    Di Bisceglie, Adrian M.
    Kowdley, Kris V.
    Floyd, Elson S.
    HEPATOLOGY, 2021, 74 : 73A - 73A
  • [2] Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia
    Di Bisceglie, Adrian M.
    Watts, Gerald F.
    Lavin, Philip
    Yu, Meng
    Bai, Ru
    Liu, Liping
    LIPIDS IN HEALTH AND DISEASE, 2020, 19 (01)
  • [3] Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia
    Adrian M. Di Bisceglie
    Gerald F. Watts
    Philip Lavin
    Meng Yu
    Ru Bai
    Liping Liu
    Lipids in Health and Disease, 19
  • [4] HTD1801 A NOVEL TREATMENT FOR NAFLD/NASH AND PRIMARY SCLEROSING CHOLANGITIS (PSC)
    Liu, Liping
    Bai, Ru
    Yu, Li
    Yu, Meng
    Fu, Xinxiang
    HEPATOLOGY, 2019, 70 : 1261A - 1262A
  • [5] EFFECTS OF HTD1801 (BERBERINE URSODEOXYCHOLATE) ON NON-INVASIVE FIBROSIS MARKERS IN SUBJECTS WITH PRESUMED NASH AND TYPE 2 DIABETES
    Harrison, Stephen A.
    Gunn, Nadege
    Neff, Guy W.
    MacConell, Leigh
    Loomba, Rohit
    HEPATOLOGY, 2021, 74 : 1136A - 1137A
  • [6] Efficacy of berberine ursodeoxycholate (HTD1801) in Chinese and Western patients with type 2 diabetes
    Gan, S.
    Ji, L.
    Ma, J.
    Cheng, Z.
    Gunn, N. T.
    Neff, G. W.
    Liu, K.
    MacConell, L.
    DIABETOLOGIA, 2024, 67 : S341 - S341
  • [7] A Dose-Finding, Positive Proof of Concept study of HTD1801 in Patients with Primary Sclerosing Cholangitis
    Kowdley, Kris
    Forman, Lisa
    Eksteen, Bertus
    Gunn, Nadege T.
    Sundaram, Vinay
    Landis, Charles
    Harrison, Stephen
    Kohli, Anita
    Levy, Cynthia
    Di Bisceglie, Adrian
    Hirschfield, Gideon
    JOURNAL OF HEPATOLOGY, 2021, 75 : S424 - S424
  • [8] GREATER BIOCHEMICAL IMPROVEMENTS WITH HTD1801 (BERBERINE URSODEOXYCHOLATE) IN PATIENTS WITH PSC AND ELEVATED BASELINE ALKALINE PHOSPHATASE
    Forman, Lisa
    Kowdley, Kris V.
    Eksteen, Bertus
    Gunn, Nadege
    Sundaram, Vinay
    Landis, Charles
    Harrison, Stephen A.
    Levy, Cynthia
    Liberman, Alexander
    Di Bisceglie, Adrian M.
    Hirschfield, Gideon
    HEPATOLOGY, 2022, 76 : S1470 - S1472
  • [9] Berberine ursodeoxycholate (HTD1801) provides a unique therapeutic approach for patients with metabolic diseases and severe insulin resistance
    MacConell, L.
    Liberman, A.
    Flyer, A.
    Liu, K.
    DIABETOLOGIA, 2024, 67 : S339 - S339
  • [10] Berberine Ursodeoxycholate (HTD1801) provides a unique therapeutic approach for patients with metabolic diseases and severe insulin resistance
    MacConell, Leigh
    Liberman, Alexander
    Flyer, Abigail
    Liu, Kui
    JOURNAL OF HEPATOLOGY, 2024, 80 : S614 - S614
123